Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120379 | 1.00 | DHFR (0.48) | DHFRFFAR1FFAR4TSHRPPARG | |
| SCHEMBL1229002 | 0.96 | DHFR (0.53) | DHFRFFAR1PPARGPPARDPPARA | |
| SCHEMBL2046234 | 0.94 | PPARA (0.52) | DHFRFFAR1PPARGPPARDPPARA | |
| SCHEMBL30215712 | 0.89 | CD274 (0.46) | DHFRFFAR1 | |
| SCHEMBL16301494 | 0.89 | PDE3B (0.43) | FFAR1 | |
| Aminodiphenylmethane SCHEMBL1963354 | 0.88 | NR1H3 (0.46) | DHFRFFAR1FFAR4PTPN1 | |
| SCHEMBL17593842 | 0.87 | DHFR (0.50) | DHFRFFAR1FFAR4TSHRPPARG | |
| SCHEMBL10335441 | 0.85 | LMNA (0.53) | DHFRFFAR1FFAR4TSHRPPARG | |
| SCHEMBL12036216 | 0.85 | CNR1 (0.48) | — | |
| SCHEMBL6599701 | 0.84 | BRD4 (0.52) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104593-A1 | FRAGMENT BASED SYNTHESIS OF PEPTIDES SUCH AS LL37 | NEUROINNOVATECH APS (DK) | 2026-05-21 | — | — | WO | claimed |
| US-12577200-B2 | High-throughput method to rapidly add chemical moieties to a small molecule library | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-17 | — | — | US | claimed |
| EP-4683911-A1 | NOVEL TAG FOR LIQUID-PHASE PEPTIDE SYNTHESIS | CordenPharma International GmbH (DE) | 2026-01-28 | — | — | EP | claimed |
| US-20250340587-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) | 2025-11-06 | — | — | US | claimed |
| WO-2025094036-A1 | A PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | PIRAMAL PHARMA LIMITED (IN) | 2025-05-08 | — | — | WO | claimed |
| EP-4532509-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | Polypeptide Laboratories Holding (PPL) AB (SE) | 2025-04-09 | — | — | EP | claimed |
| CN-119431135-B | Preparation method of 4- (4-hydroxymethyl-3-methoxyphenoxy) butyric acid | 安徽昊帆生物有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119431135-A | Preparation method of 4- (4-hydroxymethyl-3-methoxyphenoxy) butyric acid | 安徽昊帆生物有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119405828-A | Application of PD-L1 targeting affibody-nano drug conjugate in preparation of drugs for diagnosing and treating colon cancer | 山东第一医科大学(山东省医学科学院) | 2025-02-11 | — | — | CN | claimed |
| CN-119386209-A | HMPB/FA nano system with multienzyme activity and preparation method thereof | 广东省第二人民医院（广东省卫生应急医院） | 2025-02-07 | — | — | CN | claimed |
| US-11571456-B2 | Process for the linear synthesis of gram-positive class II bacteriocins and compositions and uses thereof | UNIVERSITé LAVAL (CA) | 2023-02-07 | — | — | US | claimed |
| EP-4100007-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2022-12-14 | — | — | EP | claimed |
| CN-115461054-A | Elongation factor 1-alpha inhibitor and application thereof | 加利福尼亚大学董事会 | 2022-12-09 | — | — | CN | claimed |
| CN-114163843-B | Preparation method of HMPB, prussian blue-based fluorescent probe and preparation method thereof | 中国科学院上海硅酸盐研究所 | 2022-11-25 | — | — | CN | claimed |
| CN-113150108-B | Solid-phase synthesis method of liraglutide | 台州吉诺生物科技有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-113444164-B | Solid-phase synthesis method of Somalutide | 台州吉诺生物科技有限公司 | 2022-07-19 | — | — | CN | claimed |
| EP-3405476-B1 | METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER | POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) | 2022-05-18 | — | — | EP | claimed |
| WO-2022060459-A1 | HIGH-THROUGHPUT METHOD TO RAPIDLY ADD CHEMICAL MOIETIES TO A SMALL MOLECULE LIBRARY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-24 | — | — | WO | claimed |
| US-20220089537-A1 | HIGH-THROUGHPUT METHOD TO RAPIDLY ADD CHEMICAL MOIETIES TO A SMALL MOLECULE LIBRARY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-03-24 | — | — | US | claimed |
| CN-114163843-A | Preparation method of HMPB, Prussian blue-based fluorescent probe and preparation method thereof | 中国科学院上海硅酸盐研究所 | 2022-03-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089537-A1 | HIGH-THROUGHPUT METHOD TO RAPIDLY ADD CHEMICAL MOIETIES TO A SMALL MOLECULE LIBRARY | PDE8B, ACP1, BLVRB | DHFR 84/4885FFAR1 3307/4885FFAR4 2801/4885 |
| US-20250340587-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | SSU72, CPSF6, IDUA | DHFR 528/4885FFAR1 3318/4885FFAR4 3611/4885 |
| US-11571456-B2 | Process for the linear synthesis of gram-positive class II bacteriocins and compositions and uses thereof | PSAP, SBDS, MRPL21 | DHFR 2512/4885FFAR1 4646/4885FFAR4 4477/4885 |
| US-12577200-B2 | High-throughput method to rapidly add chemical moieties to a small molecule library | CBR3, CBR1, NR2E3 | DHFR 847/4885FFAR1 1349/4885FFAR4 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.